A synbiotic mixture of scGOS/lcFOS and Bifidobacterium breve M-16V increases faecal Bifidobacterium in healthy young children.

Little is known about the impact of nutrition on toddler gut microbiota. The plasticity of the toddler gut microbiota indicates that nutritional modulation beyond infancy could potentially impact its maturation. The objective of this study was to determine the effect of consuming Young Child Formula (YCF) supplemented with short chain galactooligosaccharides and long chain fructooligosaccharides (scGOS/lcFOS, ratio 9:1) and Bifidobacterium breve M-16V on the development of the faecal microbiota in healthy toddlers. A cohort of 129 Thai children aged 1-3 years were included in a randomised controlled clinical study. The children were assigned to receive either YCF with 0.95 g/100 ml of scGOS/lcFOS and 1.8×107 cfu/g of B. breve M-16V (Active-YCF) or Control-YCF for 12 weeks. The composition and metabolic activity of the faecal microbiota, and the level of secretory immunoglobulin A were determined in the stool samples. The consumption of Active-YCF increased the proportion of Bifidobacterium (mean 27.3% at baseline to 33.3%, at week 12, P=0.012) with a difference in change from baseline at week 12 between the Active and Control of 7.48% (P=0.030). The consumption of Active-YCF was accompanied with a more acidic intestinal milieu compared to the Control-YCF. The pH value decreased statistically significantly in the Active-YCF group from a median of 7.05 at baseline to 6.79 at week 12 (P<0.001). The consumption of Active-YCF was associated with a softer pudding-like stool consistency compared to the Control-YCF. At week 6 and week 12, the between-group difference in stool consistency was statistically significant (P=0.004 and P<0.001, respectively). A Young Child Formula supplemented with scGOS/lcFOS and B. breve M-16V positively influences the development of the faecal microbiota in healthy toddlers by supporting higher levels of Bifidobacterium. The synbiotic supplementation is also accompanied with a more acidic intestinal milieu and softer stools.

Cutaneous complications of BCG vaccination in infants with immune disorders: two cases and a review of the literature.

Two infants, one with a T-cell-signaling defect resulting in a primary immunodeficiency syndrome and the other with severe combined immunodeficiency (SCID), are described. Both infants developed cutaneous infections secondary to their bacillus Calmette-Guérin (BCG) vaccinations. Both patients were from countries where BCG is routinely administered in infancy. The infant with the T-cell-signaling defect developed a disseminated infection involving the skin, while the infant with SCID developed a localized cutaneous infection at the site of his BCG immunization. These two cases resemble other reported cases of cutaneous BCG infection following routine vaccination in immunocompromised patients. Mycobacterium bovis infection should be considered in patients with cutaneous eruptions who have received BCG vaccination, especially those who are immunocompromised.

Complete mattress encasing is not superior to partial encasing in the reduction of mite allergen.

BACKGROUND: Partial mattress encasing was found to be effective in reducing exposure to mite allergen in our previous investigation. We aimed to compare the short-term efficacy of partial and complete mattress encasing and to study mite-allergen levels within these mattresses. METHODS: Thirty-one mattresses with high mite-allergen content were selected and were randomized into one of three study groups (10 for the control group [CG], 11 for the partial encasing group [PE], and 10 for the complete encasing group [CE]). A special mite-impermeable membrane was used. In the PE group, mattresses were encased on tops and sides only, whereas complete mattress encasement was undertaken in the CE group. Regular bedsheets were applied to all groups. Dust samples were collected over bedsheets at baseline and at months 3 and 6, and over mattresses at baseline and at the end of the study. Group I mite allergens in these samples were measured and compared. RESULTS: At baseline, mattress mite allergens were similar in all groups (P=0.84). Mite allergen at the surfaces of bedsheets (over membranes) from both encasing groups were significantly reduced as compared to the CG group (P=0.003). Such reduction was maintained throughout the 6-month study. At the end of the study, mite antigens within mattresses in the CG and CE groups were increased as compared to baselines, whereas a decrease was observed in the PE group. Significant difference was observed only between the CG and PE groups (P=0.006). CONCLUSIONS: Mattress encasing with a special membrane in this study was highly efficacious in the reduction of mite allergen (>90%). However, with complete encasing, mite allergens within mattresses were increased at the end of the study. Complete mattress encasing in a tropical environment does not offer any advantage over partial encasing.